OKYO Pharma Announces Chairman Acquires Shares
OKYO Pharma (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing innovative ocular therapies, has announced a significant insider purchase. Gabriele Cerrone, the Executive Chairman, through Panetta Partners , acquired 50,000 ordinary shares at $1.03 per share on NASDAQ. This transaction has increased Cerrone's total shareholding to 9,851,570 shares, representing 29.12% of the company's issued share capital.
OKYO Pharma specializes in treatments for inflammatory dry eye disease (DED), a multi-billion-dollar market, and neuropathic corneal pain (NCP), an ocular condition currently lacking FDA-approved therapies. This insider purchase may signal confidence in the company's future prospects and ongoing clinical developments.
OKYO Pharma (NASDAQ: OKYO), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie oculari innovative, ha annunciato un acquisto significativo da parte di un insider. Gabriele Cerrone, il Presidente Esecutivo, attraverso Panetta Partners, ha acquistato 50.000 azioni ordinarie a $1,03 per azione su NASDAQ. Questa transazione ha aumentato la quota totale di Cerrone a 9.851.570 azioni, rappresentando il 29,12% del capitale sociale emesso dall'azienda.
OKYO Pharma si specializza nei trattamenti per la malattia infiammatoria dell'occhio secco (DED), un mercato da miliardi di dollari, e per il dolore corneale neuropatico (NCP), una condizione oculare attualmente priva di terapie approvate dalla FDA. Questo acquisto da parte di un insider potrebbe segnalare fiducia nelle prospettive future dell'azienda e nei suoi sviluppi clinici in corso.
OKYO Pharma (NASDAQ: OKYO), una empresa biofarmacéutica en etapa clínica centrada en desarrollar terapias oculares innovadoras, ha anunciado una compra significativa por parte de un insider. Gabriele Cerrone, el Presidente Ejecutivo, a través de Panetta Partners, adquirió 50,000 acciones ordinarias a $1.03 por acción en NASDAQ. Esta transacción ha incrementado la participación total de Cerrone a 9,851,570 acciones, representando el 29.12% del capital social emitido de la empresa.
OKYO Pharma se especializa en tratamientos para la enfermedad ocular seca inflamatoria (DED), un mercado multimillonario, y para el dolor corneal neuropático (NCP), una condición ocular que actualmente carece de terapias aprobadas por la FDA. Esta compra por parte de un insider podría señalar confianza en las perspectivas futuras de la empresa y en sus desarrollos clínicos en curso.
OKYO Pharma (NASDAQ: OKYO)는 혁신적인 안과 치료제를 개발하는 임상 단계의 바이오 제약 회사로, 중요한 내부자 구매를 발표했습니다. 가브리엘레 체론 회장은 Panetta Partners를 통해 NASDAQ에서 50,000주의 보통주를 주당 $1.03에 인수했습니다. 이 거래로 Cerrone의 총 주식 보유량은 9,851,570주로 증가했으며, 이는 회사의 발행 주식 자본의 29.12%에 해당합니다.
OKYO Pharma는 수십억 달러 규모의 시장인 염증성 안구 건조증(DED) 및 현재 FDA 승인 치료제가 부족한 안과 질환인 신경병증 각막 통증(NCP)에 대한 치료에 전문화되어 있습니다. 이 내부자 구매는 회사의 미래 전망과 진행 중인 임상 개발에 대한 신뢰를 나타낼 수 있습니다.
OKYO Pharma (NASDAQ: OKYO), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies oculaires innovantes, a annoncé un achat important par un initié. Gabriele Cerrone, le président exécutif, a acquis 50 000 actions ordinaires au prix de $1,03 par action sur NASDAQ via Panetta Partners. Cette transaction a augmenté la participation totale de Cerrone à 9 851 570 actions, représentant 29,12 % du capital social émis de l'entreprise.
OKYO Pharma se spécialise dans les traitements de la maladie oculaire sèche inflammatoire (DED), un marché de plusieurs milliards de dollars, et de la douleur cornéenne neuropathique (NCP), une condition oculaire qui manque actuellement de thérapies approuvées par la FDA. Cet achat par un initié pourrait signaler une confiance dans les perspectives futures de l'entreprise et dans ses développements cliniques en cours.
OKYO Pharma (NASDAQ: OKYO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung innovativer Augenheilmittel konzentriert, hat einen bedeutenden Insider-Kauf bekannt gegeben. Gabriele Cerrone, der Vorstandsvorsitzende, hat über Panetta Partners 50.000 Stammaktien zum Preis von $1,03 pro Aktie an der NASDAQ erworben. Diese Transaktion hat Cerrones Gesamtanteil auf 9.851.570 Aktien erhöht, was 29,12% des ausgegebenen Aktienkapitals des Unternehmens entspricht.
OKYO Pharma ist auf die Behandlung von entzündlicher trockener Augenkrankheit (DED), einem Markt von mehreren Milliarden Dollar, und neuropathischen Hornhautschmerzen (NCP), einer Augenkrankheit, die derzeit an FDA-zugelassenen Therapien fehlt, spezialisiert. Dieser Insider-Kauf könnte Vertrauen in die zukünftigen Aussichten des Unternehmens und in die laufenden klinischen Entwicklungen signalisieren.
- Executive Chairman increased stake, potentially signaling confidence in the company
- Insider now owns 29.12% of the company's issued share capital
- Company targets multi-billion-dollar market for dry eye disease
- None.
LONDON and NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announced today that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, purchased 50,000 of the Company’s ordinary shares on NASDAQ at a price of US
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy signals in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
How many shares did OKYO Pharma's Chairman acquire and at what price?
What percentage of OKYO Pharma does the Chairman now own after the recent purchase?
What are the main therapeutic areas OKYO Pharma (OKYO) is focusing on?
Is there an FDA-approved therapy for neuropathic corneal pain that OKYO Pharma is targeting?
